Chronic obstructive pulmonary disease

"Emphysema" redirects here. For other uses, see Emphysema (disambiguation).

Chronic obstructive pulmonary disease
chronic obstructive lung disease (COLD), chronic obstructive airway disease (COAD), chronic bronchitis, emphysema, pulmonary emphysema, others

Gross pathology of a lung showing centrilobular-type emphysema characteristic of smoking. This close-up of the fixed, cut lung surface shows multiple cavities filled with heavy black carbon deposits.
Classification and external resources
Specialty Pulmonology
ICD-10 J40–J44, J47
ICD-9-CM 490–492, 494–496
OMIM 606963
DiseasesDB 2672
MedlinePlus 000091
eMedicine med/373 emerg/99
Patient UK Chronic obstructive pulmonary disease
MeSH C08.381.495.389

Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease characterized by long-term poor airflow. The main symptoms include shortness of breath and cough with sputum production. COPD typically worsens over time.[1] Eventually walking up stairs or carrying things will be difficult.[2] Chronic bronchitis and emphysema are older terms used for different types of COPD.[2][3] The term "chronic bronchitis" is still used to define a productive cough that is present for at least three months each year for two years.[4]

Tobacco smoking is the most common cause of COPD, with a number of other factors such as air pollution and genetics playing a smaller role.[5] In the developing world, one of the common sources of air pollution is poorly vented heating and cooking fires.[2] Long-term exposure to these irritants causes an inflammatory response in the lungs resulting in narrowing of the small airways and breakdown of lung tissue.[6] The diagnosis is based on poor airflow as measured by lung function tests.[7] In contrast to asthma, the airflow reduction does not improve much with the use of a bronchodilator.[2]

Most cases of COPD can be prevented by reducing exposure to risk factors.[8] This includes decreasing rates of smoking and improving indoor and outdoor air quality. While treatment can slow worsening, there is no cure.[2] COPD treatments include stopping smoking, vaccinations, respiratory rehabilitation, and often inhaled bronchodilators and steroids.[5] Some people may benefit from long-term oxygen therapy or lung transplantation.[6] In those who have periods of acute worsening, increased use of medications and hospitalization may be needed.[5]

As of 2013 COPD affects 329 million people or nearly 5 percent of the global population.[9][10] It typically occurs in people over the age of 40. Males and females are affected equally commonly.[2] In 2013 it resulted in 2.9 million deaths, up from 2.4 million deaths in 1990.[11] More than 90% of these deaths occur in the developing world.[2] The number of deaths is projected to increase further because of higher smoking rates in the developing world, and an aging population in many countries.[12] It resulted in an estimated economic cost of $2.1 trillion in 2010.[13]

Video explanation

Signs and symptoms
Wheezing
The sound of wheezing as heard with a stethoscope.
Problems playing this file? See media help.

The most common symptoms of COPD are sputum production, shortness of breath, and a productive cough.[14] These symptoms are present for a prolonged period of time[15] and typically worsen over time.[6] It is unclear if different types of COPD exist.[5] While previously divided into emphysema and chronic bronchitis, emphysema is only a description of lung changes rather than a disease itself, and chronic bronchitis is simply a descriptor of symptoms that may or may not occur with COPD.[1]

Cough

A chronic cough is often the first symptom to develop. When it persists for more than three months each year for at least two years, in combination with sputum production and without another explanation, there is by definition chronic bronchitis. This condition can occur before COPD fully develops. The amount of sputum produced can change over hours to days. In some cases, the cough may not be present or may only occur occasionally and may not be productive. Some people with COPD attribute the symptoms to a "smoker's cough". Sputum may be swallowed or spat out, depending often on social and cultural factors. Vigorous coughing may lead to rib fractures or a brief loss of consciousness. Those with COPD often have a history of "common colds" that last a long time.[14]

Shortness of breath

Shortness of breath is often the symptom that most bothers people.[16] It is commonly described as: "my breathing requires effort," "I feel out of breath," or "I can't get enough air in".[17] Different terms, however, may be used in different cultures.[14] Typically the shortness of breath is worse on exertion of a prolonged duration and worsens over time.[14] In the advanced stages, it occurs during rest and may be always present.[18][19] It is a source of both anxiety and a poor quality of life in those with COPD.[14] Many people with more advanced COPD breathe through pursed lips and this action can improve shortness of breath in some.[20][21]

Other features

In COPD, it may take longer to breathe out than to breathe in.[22] Chest tightness may occur[14] but is not common and may be caused by another problem.[16] Those with obstructed airflow may have wheezing or decreased sounds with air entry on examination of the chest with a stethoscope.[22] A barrel chest is a characteristic sign of COPD, but is relatively uncommon.[22] Tripod positioning may occur as the disease worsens.[15]

Advanced COPD leads to high pressure on the lung arteries, which strains the right ventricle of the heart.[6][23][24] This situation is referred to as cor pulmonale, and leads to symptoms of leg swelling[14] and bulging neck veins.[6] COPD is more common than any other lung disease as a cause of cor pulmonale.[23] Cor pulmonale has become less common since the use of supplemental oxygen.[15]

COPD often occurs along with a number of other conditions, due in part to shared risk factors.[5] These conditions include ischemic heart disease, high blood pressure, diabetes mellitus, muscle wasting, osteoporosis, lung cancer, anxiety disorder, and depression.[5] In those with severe disease, a feeling of always being tired is common.[14] Fingernail clubbing is not specific to COPD and should prompt investigations for an underlying lung cancer.[25]

Exacerbation

An acute exacerbation of COPD is defined as increased shortness of breath, increased sputum production, a change in the color of the sputum from clear to green or yellow, or an increase in cough in someone with COPD.[22] This may present with signs of increased work of breathing such as fast breathing, a fast heart rate, sweating, active use of muscles in the neck, a bluish tinge to the skin, and confusion or combative behavior in very severe exacerbations.[22][26] Crackles may also be heard over the lungs on examination with a stethoscope.[27]

Cause

The primary cause of COPD is tobacco smoke, with occupational exposure and pollution from indoor fires being significant causes in some countries.[1] Typically these exposures must occur over several decades before symptoms develop.[1] A person's genetic makeup also affects the risk.[1]

Smoking

Percentage of females smoking tobacco as of the late 1990s early 2000s
Percentage of males smoking tobacco as of the late 1990s and early 2000s. Note the scales used for females and males differ.[28]

The primary risk factor for COPD globally is tobacco smoking.[1] Of those who smoke about 20% will get COPD,[29] and of those who are lifelong smokers about half will get COPD.[30] In the United States and United Kingdom, of those with COPD, 80–95% are either current smokers or previously smoked.[29][31][32] The likelihood of developing COPD increases with the total smoke exposure.[33] Additionally, women are more susceptible to the harmful effects of smoke than men.[32] In non-smokers, secondhand smoke is the cause of about 20% of cases.[31] Other types of smoke, such as marijuana, cigar, and water pipe smoke, also confer a risk.[1] Water pipe smoke appears to be as harmful as smoking cigarettes.[34] Problems from marijuana smoke may only be with heavy use.[35] Women who smoke during pregnancy may increase the risk of COPD in their child.[1]

Air pollution

Poorly ventilated cooking fires, often fueled by coal or biomass fuels such as wood and animal dung, lead to indoor air pollution and are one of the most common causes of COPD in developing countries.[36] These fires are a method of cooking and heating for nearly 3 billion people with their health effects being greater among women due to more exposure.[1][36] They are used as the main source of energy in 80% of homes in India, China and sub-Saharan Africa.[8]

People who live in large cities have a higher rate of COPD compared to people who live in rural areas.[37] While urban air pollution is a contributing factor in exacerbations, its overall role as a cause of COPD is unclear.[1] Areas with poor outdoor air quality, including that from exhaust gas, generally have higher rates of COPD.[8] The overall effect in relation to smoking, however, is believed to be small.[1]

Occupational exposures

Intense and prolonged exposure to workplace dusts, chemicals and fumes increase the risk of COPD in both smokers and nonsmokers.[38] Workplace exposures are believed to be the cause in 10–20% of cases.[39] In the United States they are believed to be related to more than 30% of cases among those who have never smoked and probably represent a greater risk in countries without sufficient regulations.[1]

A number of industries and sources have been implicated, including[8] high levels of dust in coal mining, gold mining, and the cotton textile industry, occupations involving cadmium and isocyanates, and fumes from welding.[38] Working in agriculture is also a risk.[8] In some professions the risks have been estimated as equivalent to that of one half to two packs of cigarettes a day.[40] Silica dust exposure can also lead to COPD, with the risk unrelated to that for silicosis.[41] The negative effects of dust exposure and cigarette smoke exposure appear to be additive or possibly more than additive.[40]

Genetics

Genetics play a role in the development of COPD.[1] It is more common among relatives of those with COPD who smoke than unrelated smokers.[1] Currently, the only clearly inherited risk factor is alpha 1-antitrypsin deficiency (AAT).[42] This risk is particularly high if someone deficient in alpha 1-antitrypsin also smokes.[42] It is responsible for about 1–5% of cases[42][43] and the condition is present in about 3–4 in 10,000 people.[15] Other genetic factors are being investigated,[42] of which there are likely to be many.[8]

Other

A number of other factors are less closely linked to COPD. The risk is greater in those who are poor, although it is not clear if this is due to poverty itself or other risk factors associated with poverty, such as air pollution and malnutrition.[1] There is tentative evidence that those with asthma and airway hyperreactivity are at increased risk of COPD.[1] Birth factors such as low birth weight may also play a role as do a number of infectious diseases including HIV/AIDS and tuberculosis.[1] Respiratory infections such as pneumonia do not appear to increase the risk of COPD, at least in adults.[15]

Exacerbations

An acute exacerbation (a sudden worsening of symptoms)[44] is commonly triggered by infection or environmental pollutants, or sometimes by other factors such as improper use of medications.[45] Infections appear to be the cause of 50 to 75% of cases,[45][46] with bacteria in 25%, viruses in 25%, and both in 25%.[47] Environmental pollutants include both poor indoor and outdoor air quality.[45] Exposure to personal smoke and secondhand smoke increases the risk.[8] Cold temperature may also play a role, with exacerbations occurring more commonly in winter.[48] Those with more severe underlying disease have more frequent exacerbations: in mild disease 1.8 per year, moderate 2 to 3 per year, and severe 3.4 per year.[49] Those with many exacerbations have a faster rate of deterioration of their lung function.[50] Pulmonary emboli (blood clots in the lungs) can worsen symptoms in those with pre-existing COPD.[5] Signs of PE in COPD include pleuritic chest pain and heart failure without signs of infection.[51]

Pathophysiology

On the left is a diagram of the lungs and airways with an inset showing a detailed cross-section of normal bronchioles and alveoli. On the right are lungs damaged by COPD with an inset showing a cross-section of damaged bronchioles and alveoli.

COPD is a type of obstructive lung disease in which chronic incompletely reversible poor airflow (airflow limitation) and inability to breathe out fully (air trapping) exist.[5] The poor airflow is the result of breakdown of lung tissue (known as emphysema) and small airways disease (known as obstructive bronchiolitis). The relative contributions of these two factors vary between people.[1] Severe destruction of small airways can lead to the formation of large air pockets—known as bullae—that replace lung tissue. This form of disease is called bullous emphysema.[52]

Micrograph showing emphysema (left – large empty spaces) and lung tissue with relative preservation of the alveoli (right)

COPD develops as a significant and chronic inflammatory response to inhaled irritants.[1] Chronic bacterial infections may also add to this inflammatory state.[50] The inflammatory cells involved include neutrophil granulocytes and macrophages, two types of white blood cell. Those who smoke additionally have Tc1 lymphocyte involvement and some people with COPD have eosinophil involvement similar to that in asthma. Part of this cell response is brought on by inflammatory mediators such as chemotactic factors. Other processes involved with lung damage include oxidative stress produced by high concentrations of free radicals in tobacco smoke and released by inflammatory cells, and breakdown of the connective tissue of the lungs by proteases that are insufficiently inhibited by protease inhibitors. The destruction of the connective tissue of the lungs is what leads to emphysema, which then contributes to the poor airflow and, finally, poor absorption and release of respiratory gases.[1] General muscle wasting that often occurs in COPD may be partly due to inflammatory mediators released by the lungs into the blood.[1]

Narrowing of the airways occurs due to inflammation and scarring within them. This contributes to the inability to breathe out fully. The greatest reduction in air flow occurs when breathing out, as the pressure in the chest is compressing the airways at this time.[53] This can result in more air from the previous breath remaining within the lungs when the next breath is started, resulting in an increase in the total volume of air in the lungs at any given time, a process called hyperinflation or air trapping.[53][54] Hyperinflation from exercise is linked to shortness of breath in COPD, as it is less comfortable to breathe in when the lungs are already partly full.[55] Hyperinflation may also worsen during an exacerbation.[56]

Some also have a degree of airway hyperresponsiveness to irritants similar to those found in asthma.[15]

Low oxygen levels and, eventually, high carbon dioxide levels in the blood can occur from poor gas exchange due to decreased ventilation from airway obstruction, hyperinflation and a reduced desire to breathe.[1] During exacerbations, airway inflammation is also increased, resulting in increased hyperinflation, reduced expiratory airflow and worsening of gas transfer. This can also lead to insufficient ventilation and, eventually, low blood oxygen levels.[6] Low oxygen levels, if present for a prolonged period, can result in narrowing of the arteries in the lungs, while emphysema leads to breakdown of capillaries in the lungs. Both these changes result in increased blood pressure in the pulmonary arteries, which may cause cor pulmonale.[1]

Diagnosis

A person sitting and blowing into a device attached to a computer
A person blowing into a spirometer. Smaller handheld devices are available for office use.

The diagnosis of COPD should be considered in anyone over the age of 35 to 40 who has shortness of breath, a chronic cough, sputum production, or frequent winter colds and a history of exposure to risk factors for the disease.[14][16] Spirometry is then used to confirm the diagnosis.[14][57] Screening those without symptoms is not recommended.[58]

Spirometry

Spirometry measures the amount of airflow obstruction present and is generally carried out after the use of a bronchodilator, a medication to open up the airways.[57] Two main components are measured to make the diagnosis: the forced expiratory volume in one second (FEV1), which is the greatest volume of air that can be breathed out in the first second of a breath, and the forced vital capacity (FVC), which is the greatest volume of air that can be breathed out in a single large breath.[59] Normally, 75–80% of the FVC comes out in the first second[59] and a FEV1/FVC ratio of less than 70% in someone with symptoms of COPD defines a person as having the disease.[57] Based on these measurements, spirometry would lead to over-diagnosis of COPD in the elderly.[57] The National Institute for Health and Care Excellence criteria additionally require a FEV1 of less than 80% of predicted.[16]

Evidence for using spirometry among those without symptoms in an effort to diagnose the condition earlier is of uncertain effect and is therefore currently not recommended.[14][57] A peak expiratory flow (the maximum speed of expiration), commonly used in asthma, is not sufficient for the diagnosis of COPD.[16]

Severity

MRC shortness of breath scale[16]
Grade Activity affected
1 Only strenuous activity
2 Vigorous walking
3 With normal walking
4 After a few minutes of walking
5 With changing clothing
GOLD grade[14]
Severity FEV1 % predicted
Mild (GOLD 1) ≥80
Moderate (GOLD 2) 50–79
Severe (GOLD 3) 30–49
Very severe (GOLD 4) <30

There are a number of methods to determine how much COPD is affecting a given individual.[14] The modified British Medical Research Council questionnaire (mMRC) or the COPD assessment test (CAT) are simple questionnaires that may be used to determine the severity of symptoms.[14] Scores on CAT range from 0–40 with the higher the score, the more severe the disease.[60] Spirometry may help to determine the severity of airflow limitation.[14] This is typically based on the FEV1 expressed as a percentage of the predicted "normal" for the person's age, gender, height and weight.[14] Both the American and European guidelines recommended partly basing treatment recommendations on the FEV1.[57] The GOLD guidelines suggest dividing people into four categories based on symptoms assessment and airflow limitation.[14] Weight loss and muscle weakness, as well as the presence of other diseases, should also be taken into account.[14]

Other tests

A chest X-ray and complete blood count may be useful to exclude other conditions at the time of diagnosis.[61] Characteristic signs on X-ray are overexpanded lungs, a flattened diaphragm, increased retrosternal airspace, and bullae while it can help exclude other lung diseases, such as pneumonia, pulmonary edema or a pneumothorax.[62] A high-resolution computed tomography scan of the chest may show the distribution of emphysema throughout the lungs and can also be useful to exclude other lung diseases.[15] Unless surgery is planned, however, this rarely affects management.[15] An analysis of arterial blood is used to determine the need for oxygen; this is recommended in those with an FEV1 less than 35% predicted, those with a peripheral oxygen saturation of less than 92% and those with symptoms of congestive heart failure.[14] In areas of the world where alpha-1 antitrypsin deficiency is common, people with COPD (particularly those below the age of 45 and with emphysema affecting the lower parts of the lungs) should be considered for testing.[14]

Differential diagnosis

COPD may need to be differentiated from other causes of shortness of breath such as congestive heart failure, pulmonary embolism, pneumonia, or pneumothorax. Many people with COPD mistakenly think they have asthma.[22] The distinction between asthma and COPD is made on the basis of the symptoms, smoking history, and whether airflow limitation is reversible with bronchodilators at spirometry.[63] Tuberculosis may also present with a chronic cough and should be considered in locations where it is common.[14] Less common conditions that may present similarly include bronchopulmonary dysplasia and obliterative bronchiolitis.[61] Chronic bronchitis may occur with normal airflow and in this situation it is not classified as COPD.[15]

Prevention

Most cases of COPD are potentially preventable through decreasing exposure to smoke and improving air quality.[8] Annual influenza vaccinations in those with COPD reduce exacerbations, hospitalizations and death.[64][65] Pneumococcal vaccination may also be beneficial.[64]

Smoking cessation

Keeping people from starting smoking is a key aspect of preventing COPD.[66] The policies of governments, public health agencies, and anti-smoking organizations can reduce smoking rates by discouraging people from starting and encouraging people to stop smoking.[67] Smoking bans in public areas and places of work are important measures to decrease exposure to secondhand smoke and while many places have instituted bans more are recommended.[8]

In those who smoke, stopping smoking is the only measure shown to slow down the worsening of COPD.[68] Even at a late stage of the disease, it can reduce the rate of worsening lung function and delay the onset of disability and death.[69] Smoking cessation starts with the decision to stop smoking, leading to an attempt at quitting. Often several attempts are required before long-term abstinence is achieved.[67] Attempts over 5 years lead to success in nearly 40% of people.[70]

Some smokers can achieve long-term smoking cessation through willpower alone. Smoking, however, is highly addictive,[71] and many smokers need further support. The chance of quitting is improved with social support, engagement in a smoking cessation program and the use of medications such as nicotine replacement therapy, bupropion or varenicline.[67][70]

Occupational health

A number of measures have been taken to reduce the likelihood that workers in at-risk industries—such as coal mining, construction and stonemasonry—will develop COPD.[8] Examples of these measures include: the creation of public policy,[8] education of workers and management about the risks, promoting smoking cessation, checking workers for early signs of COPD, use of respirators, and dust control.[72][73] Effective dust control can be achieved by improving ventilation, using water sprays and by using mining techniques that minimize dust generation.[74] If a worker develops COPD, further lung damage can be reduced by avoiding ongoing dust exposure, for example by changing the work role.[75]

Air pollution

Both indoor and outdoor air quality can be improved, which may prevent COPD or slow the worsening of existing disease.[8] This may be achieved by public policy efforts, cultural changes, and personal involvement.[76]

A number of developed countries have successfully improved outdoor air quality through regulations. This has resulted in improvements in the lung function of their populations.[8] Those with COPD may experience fewer symptoms if they stay indoors on days when outdoor air quality is poor.[6]

One key effort is to reduce exposure to smoke from cooking and heating fuels through improved ventilation of homes and better stoves and chimneys.[76] Proper stoves may improve indoor air quality by 85%. Using alternative energy sources such as solar cooking and electrical heating is also effective. Using fuels such as kerosene or coal might be less bad than traditional biomass such as wood or dung.[8]

Management

There is no known cure for COPD, but the symptoms are treatable and its progression can be delayed.[66] The major goals of management are to reduce risk factors, manage stable COPD, prevent and treat acute exacerbations, and manage associated illnesses.[6] The only measures that have been shown to reduce mortality are smoking cessation and supplemental oxygen.[77] Stopping smoking decreases the risk of death by 18%.[5] Other recommendations include influenza vaccination once a year, pneumococcal vaccination once every 5 years, and reduction in exposure to environmental air pollution.[5] In those with advanced disease, palliative care may reduce symptoms, with morphine improving the feelings of shortness of breath.[78] Noninvasive ventilation may be used to support breathing.[78]

Exercise

Pulmonary rehabilitation is a program of exercise, disease management and counseling, coordinated to benefit the individual.[79] In those who have had a recent exacerbation, pulmonary rehabilitation appears to improve the overall quality of life and the ability to exercise, and reduce mortality.[80] It has also been shown to improve the sense of control a person has over their disease, as well as their emotions.[81] Breathing exercises in and of themselves appear to have a limited role.[21] Pursed lip breathing exercises may be useful.[20][21] Tai Chi exercises appear to be safe to practice for people with COPD, and may be beneficial for pulmonary function and pulmonary capacity when compared to a regular treatment program.[82] Tai Chi was not found to be more effective than other exercise intervention programs.[82]

Being either underweight or overweight can affect the symptoms, degree of disability and prognosis of COPD. People with COPD who are underweight can improve their breathing muscle strength by increasing their calorie intake.[6] When combined with regular exercise or a pulmonary rehabilitation program, this can lead to improvements in COPD symptoms. Supplemental nutrition may be useful in those who are malnourished.[83]

Bronchodilators

Inhaled bronchodilators are the primary medications used[5] and result in a small overall benefit.[84] There are two major types, β2 agonists and anticholinergics; both exist in long-acting and short-acting forms. They reduce shortness of breath, wheeze and exercise limitation, resulting in an improved quality of life.[85] It is unclear if they change the progression of the underlying disease.[5]

In those with mild disease, short-acting agents are recommended on an as needed basis.[5] In those with more severe disease, long-acting agents are recommended.[5] Long acting agents partly work by improving hyperinflation.[56] If long-acting bronchodilators are insufficient, then inhaled corticosteroids are typically added.[5] With respect to long-acting agents, it is unclear if tiotropium (a long-acting anticholinergic) or long-acting beta agonists (LABAs) are better, and it may be worth trying each and continuing the one that worked best.[86] Both types of agent appear to reduce the risk of acute exacerbations by 15–25%.[5] While both may be used at the same time, any benefit is of questionable significance.[87]

There are several short-acting β2 agonists available including salbutamol (Ventolin) and terbutaline.[88] They provide some relief of symptoms for four to six hours.[88] Long-acting β2 agonists such as salmeterol and formoterol are often used as maintenance therapy. Some feel the evidence of benefits is limited[89] while others view the evidence of benefit as established.[90][91] Long-term use appears safe in COPD[92] with adverse effects include shakiness and heart palpitations.[5] When used with inhaled steroids they increase the risk of pneumonia.[5] While steroids and LABAs may work better together,[89] it is unclear if this slight benefit outweighs the increased risks.[93]

There are two main anticholinergics used in COPD, ipratropium and tiotropium. Ipratropium is a short-acting agent while tiotropium is long-acting. Tiotropium is associated with a decrease in exacerbations and improved quality of life,[94] and tiotropium provides those benefits better than ipratropium.[95] It does not appear to affect mortality or the overall hospitalization rate.[96] Anticholinergics can cause dry mouth and urinary tract symptoms.[5] They are also associated with increased risk of heart disease and stroke.[97][98] Aclidinium, another long acting agent which came to market in 2012, has been used as an alternative to tiotropium.[99][100]

Corticosteroids

Corticosteroids are usually used in inhaled form but may also be used as tablets to treat and prevent acute exacerbations. While inhaled corticosteroids (ICS) have not shown benefit for people with mild COPD, they decrease acute exacerbations in those with either moderate or severe disease.[101] By themselves they have no effect on overall one-year mortality.[77][102] It is unclear if they affect the progression of the disease.[5] When used in combination with a LABA they may decrease mortality compared to either ICS or LABA alone.[103][104] Inhaled steroids are associated with increased rates of pneumonia.[105] Long-term treatment with steroid tablets is associated with significant side effects.[88]

Other medication

Long-term antibiotics, specifically those from the macrolide class such as erythromycin, reduce the frequency of exacerbations in those who have two or more a year.[106][107] This practice may be cost effective in some areas of the world.[108] Concerns include that of antibiotic resistance and hearing problems with azithromycin.[107] Methylxanthines such as theophylline generally cause more harm than benefit and thus are usually not recommended,[109] but may be used as a second-line agent in those not controlled by other measures.[6] Mucolytics may help to reduce exacerbations in some people with chronic bronchitis.[110] Cough medicines are not recommended.[88]

Oxygen

Supplemental oxygen is recommended in those with low oxygen levels at rest (a partial pressure of oxygen of less than 50–55 mmHg or oxygen saturations of less than 88%).[88][111] In this group of people it decreases the risk of heart failure and death if used 15 hours per day[88][111] and may improve people's ability to exercise.[112] In those with normal or mildly low oxygen levels, oxygen supplementation may improve shortness of breath.[113] There is a risk of fires and little benefit when those on oxygen continue to smoke.[114] In this situation some recommend against its use.[115] During acute exacerbations, many require oxygen therapy; the use of high concentrations of oxygen without taking into account a person's oxygen saturations may lead to increased levels of carbon dioxide and worsened outcomes.[116][117] In those at high risk of high carbon dioxide levels, oxygen saturations of 88–92% are recommended, while for those without this risk recommended levels are 94–98%.[117]

Surgery

For those with very severe disease, surgery is sometimes helpful and may include lung transplantation or lung volume reduction surgery.[5] Lung volume reduction surgery involves removing the parts of the lung most damaged by emphysema allowing the remaining, relatively good lung to expand and work better.[88] Volume reduction surgery seems to be particularly effective if emphysema predominantly involves the upper lobe, but the procedure increases the risks of early death and adverse events.[118] Lung transplantation is sometimes performed for very severe COPD, particularly in younger individuals.[88]

Exacerbations

Acute exacerbations are typically treated by increasing the use of short-acting bronchodilators.[5] This commonly includes a combination of a short-acting inhaled beta agonist and anticholinergic.[44] These medications can be given either via a metered-dose inhaler with a spacer or via a nebulizer with both appearing to be equally effective.[44][119] Nebulization may be easier for those who are more unwell.[44]

Oral corticosteroids improve the chance of recovery and decrease the overall duration of symptoms.[5][44] They work equally well as intravenous steroids but appear to have fewer side effects.[120] Five days of steroids work as well as ten or fourteen.[121] In those with a severe exacerbation, antibiotics improve outcomes.[122] A number of different antibiotics may be used including amoxicillin, doxycycline and azithromycin; it is unclear if one is better than the others.[64] The FDA recommends against the use of fluoroquinolones when other options are available due to higher risks of serious side effects.[123] There is no clear evidence for those with less severe cases.[122]

For those with type 2 respiratory failure (acutely raised CO2 levels) non-invasive positive pressure ventilation decreases the probability of death or the need of intensive care admission.[5] Additionally, theophylline may have a role in those who do not respond to other measures.[5] Fewer than 20% of exacerbations require hospital admission.[44] In those without acidosis from respiratory failure, home care ("hospital at home") may be able to help avoid some admissions.[44]

Prognosis

Chronic obstructive pulmonary disease deaths per million persons in 2012
  9-63
  64-80
  81-95
  96-116
  117-152
  153-189
  190-235
  236-290
  291-375
  376-1089
Disability-adjusted life years lost to chronic obstructive pulmonary disease per 100,000 inhabitants in 2004.[124]
  no data
  ≤110
  110–220
  220–330
  330–440
  440–550
  550–660
  660–770
  770–880
  880–990
  990–1100
  1100–1350
  ≥1350

COPD usually gets gradually worse over time and can ultimately result in death. It is estimated that 3% of all disability is related to COPD.[125] The proportion of disability from COPD globally has decreased from 1990 to 2010 due to improved indoor air quality primarily in Asia.[125] The overall number of years lived with disability from COPD, however, has increased.[10]

The rate at which COPD worsens varies with the presence of factors that predict a poor outcome, including severe airflow obstruction, little ability to exercise, shortness of breath, significantly underweight or overweight, congestive heart failure, continued smoking, and frequent exacerbations.[6] Long-term outcomes in COPD can be estimated using the BODE index which gives a score of zero to ten depending on FEV1, body-mass index, the distance walked in six minutes, and the modified MRC dyspnea scale.[126] Significant weight loss is a bad sign.[15] Results of spirometry are also a good predictor of the future progress of the disease but not as good as the BODE index.[15][16]

Epidemiology

Globally, as of 2010, COPD affected approximately 329 million people (4.8% of the population).[10] The disease affects men and women almost equally, as there has been increased tobacco use among women in the developed world.[127] The increase in the developing world between 1970 and the 2000s is believed to be related to increasing rates of smoking in this region, an increasing population and an aging population due to fewer deaths from other causes such as infectious diseases.[5] Some developed countries have seen increased rates, some have remained stable and some have seen a decrease in COPD prevalence.[5] The global numbers are expected to continue increasing as risk factors remain common and the population continues to get older.[66]

Between 1990 and 2010 the number of deaths from COPD decreased slightly from 3.1 million to 2.9 million[128] and became the fourth leading cause of death.[5] In 2012 it became the third leading cause as the number of deaths rose again to 3.1 million.[129] In some countries, mortality has decreased in men but increased in women.[130] This is most likely due to rates of smoking in women and men becoming more similar.[15] COPD is more common in older people;[1] it affects 34–200 out of 1000 people older than 65 years, depending on the population under review.[1][62]

In England, an estimated 0.84 million people (of 50 million) have a diagnosis of COPD; this translates into approximately one person in 59 receiving a diagnosis of COPD at some point in their lives. In the most socioeconomically deprived parts of the country, one in 32 people were diagnosed with COPD, compared with one in 98 in the most affluent areas.[131] In the United States approximately 6.3% of the adult population, totaling approximately 15 million people, have been diagnosed with COPD.[132] 25 million people may have COPD if currently undiagnosed cases are included.[133] In 2011, there were approximately 730,000 hospitalizations in the United States for COPD.[134] In the United State, COPD, is estimated to be the third leading cause of death in 2011.[135]

History

Giovanni Battista Morgagni, who made one of the earliest recorded descriptions of emphysema in 1769

The word "emphysema" is derived from the Greek ἐμφυσᾶν emphysan meaning "inflate" -itself composed of ἐν en, meaning "in", and φυσᾶν physan, meaning "breath, blast".[136] The term chronic bronchitis came into use in 1808[137] while the term COPD is believed to have first been used in 1965.[138] Previously it has been known by a number of different names, including chronic obstructive bronchopulmonary disease, chronic obstructive respiratory disease, chronic airflow obstruction, chronic airflow limitation, chronic obstructive lung disease, nonspecific chronic pulmonary disease, and diffuse obstructive pulmonary syndrome. The terms chronic bronchitis and emphysema were formally defined in 1959 at the CIBA guest symposium and in 1962 at the American Thoracic Society Committee meeting on Diagnostic Standards.[138]

Early descriptions of probable emphysema include: in 1679 by T. Bonet of a condition of "voluminous lungs" and in 1769 by Giovanni Morgagni of lungs which were "turgid particularly from air".[138][139] In 1721 the first drawings of emphysema were made by Ruysh.[139] These were followed with pictures by Matthew Baillie in 1789 and descriptions of the destructive nature of the condition. In 1814 Charles Badham used "catarrh" to describe the cough and excess mucus in chronic bronchitis. René Laennec, the physician who invented the stethoscope, used the term "emphysema" in his book A Treatise on the Diseases of the Chest and of Mediate Auscultation (1837) to describe lungs that did not collapse when he opened the chest during an autopsy. He noted that they did not collapse as usual because they were full of air and the airways were filled with mucus. In 1842, John Hutchinson invented the spirometer, which allowed the measurement of vital capacity of the lungs. However, his spirometer could only measure volume, not airflow. Tiffeneau and Pinelli in 1947 described the principles of measuring airflow.[138]

In 1953, Dr. George L. Waldbott, an American allergist, first described a new disease he named "smoker's respiratory syndrome" in the 1953 Journal of the American Medical Association. This was the first association between tobacco smoking and chronic respiratory disease.[140]

Early treatments included garlic, cinnamon and ipecac, among others.[137] Modern treatments were developed during the second half of the 20th century. Evidence supporting the use of steroids in COPD were published in the late 1950s. Bronchodilators came into use in the 1960s following a promising trial of isoprenaline. Further bronchodilators, such as salbutamol, were developed in the 1970s, and the use of LABAs began in the mid-1990s.[141]

Society and culture

COPD has been referred to as "smoker's lung".[142] People with emphysema have been known as "pink puffers" or "type A" due to their frequent pink complexion, fast respiratory rate and pursed lips,[143][144] and people with chronic bronchitis have been referred to as "blue bloaters" or "type B" due to the often bluish color of the skin and lips from low oxygen levels and their ankle swelling.[144][145] This terminology is no longer accepted as useful as most people with COPD have a combination of both emphysema and chronic bronchitis.[15][144]

Many health systems have difficulty ensuring appropriate identification, diagnosis and care of people with COPD; Britain's Department of Health has identified this as a major issue for the National Health Service and has introduced a specific strategy to tackle these problems.[146]

Economics

Globally, as of 2010, COPD is estimated to result in economic costs of $2.1 trillion, half of which occurring in the developing world.[13] Of this total an estimated $1.9 trillion are direct costs such as medical care, while $0.2 trillion are indirect costs such as missed work.[147] This is expected to more than double by the year 2030.[13] In Europe, COPD represents 3% of healthcare spending.[1] In the United States, costs of the disease are estimated at $50 billion, most of which is due to exacerbation.[1] COPD was among the most expensive conditions seen in U.S. hospitals in 2011, with a total cost of about $5.7 billion.[134]

Research

Infliximab, an immune-suppressing antibody, has been tested in COPD but there was no evidence of benefit with the possibility of harm.[148] Roflumilast shows promise in decreasing the rate of exacerbations but does not appear to change quality of life.[5] A number of new, long-acting agents are under development.[5]

Treatment with stem cells is under study.[149] While there is tentative data that it is safe and with promising animal data there is little human data as of 2014.[150][151][152] Some of the human data that is available has found poor results.[153]

A procedure known as target lung denervation, which involves decreasing the parasympathetic nervous system supply of the lungs, is being studied but does not yet have sufficient data to determine its use.[154]

Other animals

Chronic obstructive pulmonary disease may occur in a number of other animals and may be caused by exposure to tobacco smoke.[155][156] Most cases of the disease, however, are relatively mild.[157] In horses it is known as recurrent airway obstruction, can be quite severe, and most often is linked to an allergic reaction to a fungus contained in contaminated hay or straw.[158] COPD is also commonly found in old dogs.[159]

References

  1. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Vestbo, Jørgen (2013). "Definition and Overview". Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease. pp. 1–7.
  2. 1 2 3 4 5 6 7 "Chronic obstructive pulmonary disease (COPD) Fact sheet N°315". WHO. January 2015. Retrieved 4 March 2016.
  3. ↑ Craig, John A. (2012). Ferri's netter patient advisor (2nd ed.). Saunders. p. 913. ISBN 9781455728268.
  4. ↑ Global Strategy for the Diagnosis, Management, and Prevention of COPD (PDF). Global Initiative for Chronic Obstructive Lung Disease. 2016. p. 2.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Decramer M, Janssens W, Miravitlles M (April 2012). "Chronic obstructive pulmonary disease". Lancet. 379 (9823): 1341–51. doi:10.1016/S0140-6736(11)60968-9. PMID 22314182.
  6. 1 2 3 4 5 6 7 8 9 10 11 Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J (September 2007). "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary". Am. J. Respir. Crit. Care Med. 176 (6): 532–55. doi:10.1164/rccm.200703-456SO. PMID 17507545.
  7. ↑ Nathell L, Nathell M, Malmberg P, Larsson K (2007). "COPD diagnosis related to different guidelines and spirometry techniques". Respir. Res. 8 (1): 89. doi:10.1186/1465-9921-8-89. PMC 2217523Freely accessible. PMID 18053200.
  8. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Pirozzi C, Scholand MB (July 2012). "Smoking cessation and environmental hygiene". Med. Clin. North Am. 96 (4): 849–67. doi:10.1016/j.mcna.2012.04.014. PMID 22793948.
  9. ↑ Global Burden of Disease Study 2013, Collaborators (22 August 2015). "Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet. 386 (9995): 743–800. doi:10.1016/S0140-6736(15)60692-4. PMID 26063472.
  10. 1 2 3 Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, Shibuya K, Salomon JA, Abdalla S, Aboyans V, et al. (December 2012). "Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2163–96. doi:10.1016/S0140-6736(12)61729-2. PMID 23245607.
  11. ↑ GBD 2013 Mortality and Causes of Death, Collaborators (17 December 2014). "Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013.". Lancet. 385: 117–171. doi:10.1016/S0140-6736(14)61682-2. PMC 4340604Freely accessible. PMID 25530442.
  12. ↑ Mathers CD, Loncar D (November 2006). "Projections of Global Mortality and Burden of Disease from 2002 to 2030". PLoS Med. 3 (11): e442. doi:10.1371/journal.pmed.0030442. PMC 1664601Freely accessible. PMID 17132052.
  13. 1 2 3 Lomborg, Bjørn (2013). Global problems, local solutions : costs and benefits. Cambridge University Press. p. 143. ISBN 978-1-107-03959-9.
  14. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Vestbo, Jørgen (2013). "Diagnosis and Assessment" (PDF). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease. pp. 9–17.
  15. 1 2 3 4 5 6 7 8 9 10 11 12 13 Reilly, John J.; Silverman, Edwin K.; Shapiro, Steven D. (2011). "Chronic Obstructive Pulmonary Disease". In Longo, Dan; Fauci, Anthony; Kasper, Dennis; Hauser, Stephen; Jameson, J.; Loscalzo, Joseph. Harrison's Principles of Internal Medicine (18th ed.). McGraw Hill. pp. 2151–9. ISBN 978-0-07-174889-6.
  16. 1 2 3 4 5 6 7 National Institute for Health and Clinical Excellence. Clinical guideline 101: Chronic Obstructive Pulmonary Disease. London, June 2010.
  17. ↑ Mahler DA (2006). "Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease". Proceedings of the American Thoracic Society. 3 (3): 234–8. doi:10.1513/pats.200509-103SF. PMID 16636091.
  18. ↑ "What Are the Signs and Symptoms of COPD?". National Heart, Lung, and Blood Institute. July 31, 2013. Retrieved November 29, 2013.
  19. ↑ MedlinePlus Encyclopedia Chronic obstructive pulmonary disease
  20. 1 2 Morrison, [edited by] Nathan E. Goldstein, R. Sean (2013). Evidence-based practice of palliative medicine. Elsevier/Saunders. p. 124. ISBN 978-1-4377-3796-7.
  21. 1 2 3 Holland AE, Hill CJ, Jones AY, McDonald CF (2012). Holland, Anne E, ed. "Breathing exercises for chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 10: CD008250. doi:10.1002/14651858.CD008250.pub2. PMID 23076942.
  22. 1 2 3 4 5 6 Gruber, Phillip (November 2008). "The Acute Presentation of Chronic Obstructive Pulmonary Disease In the Emergency Department: A Challenging Oxymoron". Emergency Medicine Practice. 10 (11).
  23. 1 2 Weitzenblum E, Chaouat A (2009). "Cor pulmonale". Chron Respir Dis. 6 (3): 177–85. doi:10.1177/1479972309104664. PMID 19643833.
  24. ↑ "Cor pulmonale". Professional guide to diseases (9th ed.). Wolters Kluwer Health/Lippincott Williams & Wilkins. 2009. pp. 120–2. ISBN 978-0-7817-7899-2.
  25. ↑ Mandell, editors, James K. Stoller, Franklin A. Michota, Jr., Brian F. (2009). The Cleveland Clinic Foundation intensive review of internal medicine (5th ed.). Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 419. ISBN 978-0-7817-9079-6.
  26. ↑ Brulotte CA, Lang ES (May 2012). "Acute exacerbations of chronic obstructive pulmonary disease in the emergency department". Emerg. Med. Clin. North Am. 30 (2): 223–47, vii. doi:10.1016/j.emc.2011.10.005. PMID 22487106.
  27. ↑ Spiro, Stephen (2012). Clinical respiratory medicine expert consult (4th ed.). Saunders. ISBN 978-1-4557-2329-4.
  28. ↑ World Health Organization (2008). WHO Report on the Global Tobacco Epidemic 2008: The MPOWER Package (PDF). World Health Organization. pp. 268–309. ISBN 92-4-159628-7.
  29. 1 2 Ward, Helen (2012). Oxford Handbook of Epidemiology for Clinicians. Oxford University Press. pp. 289–290. ISBN 978-0-19-165478-7.
  30. ↑ Laniado-Laborín, R (January 2009). "Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21st century". International journal of environmental research and public health. 6 (1): 209–24. doi:10.3390/ijerph6010209. PMC 2672326Freely accessible. PMID 19440278.
  31. 1 2 Rennard, Stephen (2013). Clinical management of chronic obstructive pulmonary disease (2nd ed.). Informa Healthcare. p. 23. ISBN 978-0-8493-7588-0.
  32. 1 2 Anita Sharma ; with a contribution by David Pitchforth ; forewords by Gail Richards; Barclay, Joyce (2010). COPD in primary care. Radcliffe Pub. p. 9. ISBN 978-1-84619-316-3.
  33. ↑ Goldman, Lee (2012). Goldman's Cecil medicine (24th ed.). Elsevier/Saunders. p. 537. ISBN 978-1-4377-1604-7.
  34. ↑ Raad, D; Gaddam, S; Schunemann, HJ; Irani, J; Abou Jaoude, P; Honeine, R; Akl, EA (April 2011). "Effects of water-pipe smoking on lung function: a systematic review and meta-analysis.". Chest. 139 (4): 764–74. doi:10.1378/chest.10-0991. PMID 20671057.
  35. ↑ Joshi, M; Joshi, A; Bartter, T (March 2014). "Marijuana and lung diseases.". Current Opinion in Pulmonary Medicine. 20 (2): 173–9. doi:10.1097/MCP.0000000000000026. PMID 24384575.
  36. 1 2 Kennedy SM, Chambers R, Du W, Dimich-Ward H (December 2007). "Environmental and occupational exposures: do they affect chronic obstructive pulmonary disease differently in women and men?". Proceedings of the American Thoracic Society. 4 (8): 692–4. doi:10.1513/pats.200707-094SD. PMID 18073405.
  37. ↑ Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM (September 2006). "Global burden of COPD: systematic review and meta-analysis". Eur. Respir. J. 28 (3): 523–32. doi:10.1183/09031936.06.00124605. PMID 16611654.
  38. 1 2 Devereux, Graham (2006). "ABC of chronic obstructive pulmonary disease. Definition, epidemiology and risk factors". BMJ. 332 (7550): 1142–4. doi:10.1136/bmj.332.7550.1142. PMC 1459603Freely accessible. PMID 16690673.
  39. ↑ Laine, Christine (2009). In the Clinic: Practical Information about Common Health Problems. ACP Press. p. 226. ISBN 978-1-934465-64-6.
  40. 1 2 Barnes, Peter J.; Drazen, Jeffrey M.; Rennard, Stephen I.; Thomson, Neil C., eds. (2009). "Relationship between cigarette smoking and occupational exposures". Asthma and COPD: Basic Mechanisms and Clinical Management. Academic. p. 464. ISBN 978-0-12-374001-4.
  41. ↑ Rushton, Lesley (2007). "Chronic Obstructive Pulmonary Disease and Occupational Exposure to Silica". Reviews on Environmental Health. 22 (4): 255–72. doi:10.1515/REVEH.2007.22.4.255. PMID 18351226.
  42. 1 2 3 4 Foreman MG, Campos M, Celedón JC (July 2012). "Genes and chronic obstructive pulmonary disease". Med. Clin. North Am. 96 (4): 699–711. doi:10.1016/j.mcna.2012.02.006. PMC 3399759Freely accessible. PMID 22793939.
  43. ↑ Brode SK, Ling SC, Chapman KR (September 2012). "Alpha-1 antitrypsin deficiency: a commonly overlooked cause of lung disease". CMAJ. 184 (12): 1365–71. doi:10.1503/cmaj.111749. PMC 3447047Freely accessible. PMID 22761482.
  44. 1 2 3 4 5 6 7 Vestbo, Jørgen (2013). "Management of Exacerbations" (PDF). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease. pp. 39–45.
  45. 1 2 3 Dhar, Raja (2011). Textbook of pulmonary and critical care medicine. New Delhi: Jaypee Brothers Medical Publishers. p. 1056. ISBN 978-93-5025-073-0.
  46. ↑ Palange, Paolo (2013). ERS Handbook of Respiratory Medicine. European Respiratory Society. p. 194. ISBN 978-1-84984-041-5.
  47. ↑ Lötvall, Jan (2011). Advances in combination therapy for asthma and COPD. Wiley. p. 251. ISBN 978-1-119-97846-6.
  48. ↑ Barnes, Peter (2009). Asthma and COPD : basic mechanisms and clinical management (2nd ed.). Academic. p. 837. ISBN 978-0-12-374001-4.
  49. ↑ Hanania, Nicola (2010-12-09). COPD a Guide to Diagnosis and Clinical Management (1st ed.). Springer Science+Business Media, LLC. p. 197. ISBN 978-1-59745-357-8.
  50. 1 2 Beasley, V; Joshi, PV; Singanayagam, A; Molyneaux, PL; Johnston, SL; Mallia, P (2012). "Lung microbiology and exacerbations in COPD". International Journal of Chronic Obstructive Pulmonary Disease. 7: 555–69. doi:10.2147/COPD.S28286. PMC 3437812Freely accessible. PMID 22969296.
  51. ↑ Aleva, FE; Voets, LW; Simons, SO; de Mast, Q; van der Ven, AJ; Heijdra, YF (11 August 2016). "Prevalence and Localization of Pulmonary Embolism in Unexplained Acute Exacerbations of COPD: A systematic review and meta-analysis.". Chest. doi:10.1016/j.chest.2016.07.034. PMID 27522956.
  52. ↑ Murphy DM, Fishman AP (2008). "Chapter 53". Fishman's Pulmonary Diseases and Disorders (4th ed.). McGraw-Hill. p. 913. ISBN 0-07-145739-9.
  53. 1 2 Calverley PM, Koulouris NG (2005). "Flow limitation and dynamic hyperinflation: key concepts in modern respiratory physiology". Eur Respir J. 25 (1): 186–199. doi:10.1183/09031936.04.00113204. PMID 15640341.
  54. ↑ Currie, Graeme P. (2010). ABC of COPD (2nd ed.). Wiley-Blackwell, BMJ Books. p. 32. ISBN 978-1-4443-2948-3.
  55. ↑ O'Donnell DE (2006). "Hyperinflation, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease". The Proceedings of the American Thoracic Society. 3 (2): 180–4. doi:10.1513/pats.200508-093DO. PMID 16565429.
  56. 1 2 Cooper, CB (October 2006). "The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function.". The American Journal of Medicine. 119 (10 Suppl 1): 21–31. doi:10.1016/j.amjmed.2006.08.004. PMID 16996896.
  57. 1 2 3 4 5 6 Qaseem, Amir; Wilt, TJ; Weinberger, SE; Hanania, NA; Criner, G; Van Der Molen, T; Marciniuk, DD; Denberg, T; Schünemann, H; Wedzicha, W; MacDonald, R; Shekelle, P; American College Of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society (2011). "Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society". Annals of Internal Medicine. 155 (3): 179–91. doi:10.7326/0003-4819-155-3-201108020-00008. PMID 21810710.
  58. ↑ Siu, Albert L.; Bibbins-Domingo, Kirsten; Grossman, David C.; Davidson, Karina W.; Epling, John W.; García, Francisco A. R.; Gillman, Matthew; Kemper, Alex R.; Krist, Alex H.; Kurth, Ann E.; Landefeld, C. Seth; Mangione, Carol M.; Harper, Diane M.; Phillips, William R.; Phipps, Maureen G.; Pignone, Michael P. (5 April 2016). "Screening for Chronic Obstructive Pulmonary Disease". JAMA. 315 (13): 1372. doi:10.1001/jama.2016.2638.
  59. 1 2 Young, Vincent B. (2010). Blueprints medicine (5th ed.). Wolters Kluwer Health/Lippincott William & Wilkins. p. 69. ISBN 978-0-7817-8870-0.
  60. ↑ "COPD Assessment Test (CAT)". American Thoracic Society. Retrieved November 29, 2013.
  61. 1 2 National Institute for Health and Clinical Excellence. Clinical guideline 101: Chronic Obstructive Pulmonary Disease. London, June 2010.
  62. 1 2 Torres M, Moayedi S (May 2007). "Evaluation of the acutely dyspneic elderly patient". Clin. Geriatr. Med. 23 (2): 307–25, vi. doi:10.1016/j.cger.2007.01.007. PMID 17462519.
  63. ↑ BTS COPD Consortium (2005). "Spirometry in practice – a practical guide to using spirometry in primary care". pp. 8–9. Retrieved 25 August 2014.
  64. 1 2 3 Mackay AJ, Hurst JR (July 2012). "COPD exacerbations: causes, prevention, and treatment". Med. Clin. North Am. 96 (4): 789–809. doi:10.1016/j.mcna.2012.02.008. PMID 22793945.
  65. ↑ Poole PJ, Chacko E, Wood-Baker RW, Cates CJ (2006). Poole, Phillippa, ed. "Influenza vaccine for patients with chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 1: CD002733. doi:10.1002/14651858.CD002733.pub2. PMID 16437444.
  66. 1 2 3 Vestbo, Jørgen (2013). "Introduction". Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (PDF). Global Initiative for Chronic Obstructive Lung Disease. xiii–xv.
  67. 1 2 3 Policy Recommendations for Smoking Cessation and Treatment of Tobacco Dependence. World Health Organization. pp. 15–40. ISBN 978-92-4-156240-9.
  68. ↑ Jiménez-Ruiz CA, Fagerström KO (March 2013). "Smoking cessation treatment for COPD smokers: the role of counselling". Monaldi Arch Chest Dis. 79 (1): 33–7. PMID 23741944.
  69. ↑ Kumar P, Clark M (2005). Clinical Medicine (6th ed.). Elsevier Saunders. pp. 900–1. ISBN 0-7020-2763-4.
  70. 1 2 Tønnesen P (March 2013). "Smoking cessation and COPD". Eur Respir Rev. 22 (127): 37–43. doi:10.1183/09059180.00007212. PMID 23457163.
  71. ↑ "Why is smoking addictive?". NHS Choices. December 29, 2011. Retrieved November 29, 2013.
  72. ↑ Smith, Barbara K. Timby, Nancy E. (2005). Essentials of nursing : care of adults and children. Lippincott Williams & Wilkins. p. 338. ISBN 978-0-7817-5098-1.
  73. ↑ Rom, William N.; Markowitz, Steven B., eds. (2007). Environmental and occupational medicine (4th ed.). Wolters Kluwer/Lippincott Williams & Wilkins. pp. 521–2. ISBN 978-0-7817-6299-1.
  74. ↑ "Wet cutting". Health and Safety Executive. Retrieved November 29, 2013.
  75. ↑ George, Ronald B. (2005). Chest medicine : essentials of pulmonary and critical care medicine (5th ed.). Lippincott Williams & Wilkins. p. 172. ISBN 978-0-7817-5273-2.
  76. 1 2 Vestbo, Jørgen (2013). "Management of Stable COPD". Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (PDF). Global Initiative for Chronic Obstructive Lung Disease. pp. 31–8.
  77. 1 2 Drummond MB, Dasenbrook EC, Pitz MW, Murphy DJ, Fan E (November 2008). "Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis". JAMA. 300 (20): 2407–16. doi:10.1001/jama.2008.717. PMID 19033591.
  78. 1 2 Carlucci A, Guerrieri A, Nava S (December 2012). "Palliative care in COPD patients: is it only an end-of-life issue?". Eur Respir Rev. 21 (126): 347–54. doi:10.1183/09059180.00001512. PMID 23204123.
  79. ↑ "COPD — Treatment". U.S. National Heart Lung and Blood Institute. Retrieved 2013-07-23.
  80. ↑ Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J (2011). Puhan, Milo A, ed. "Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease". Cochrane Database Syst Rev (10): CD005305. doi:10.1002/14651858.CD005305.pub3. PMID 21975749.
  81. ↑ McCarthy, B; Casey, D; Devane, D; Murphy, K; Murphy, E; Lacasse, Y (23 February 2015). "Pulmonary rehabilitation for chronic obstructive pulmonary disease.". Cochrane Database Syst Rev. 2: CD003793. doi:10.1002/14651858.CD003793.pub3. PMID 25705944.
  82. 1 2 Ngai, Shirley P. C.; Jones, Alice Y. M.; Tam, Wilson Wai San (2016-06-07). "Tai Chi for chronic obstructive pulmonary disease (COPD)". The Cochrane Database of Systematic Reviews (6): CD009953. doi:10.1002/14651858.CD009953.pub2. ISSN 1469-493X. PMID 27272131.
  83. ↑ Ferreira IM, Brooks D, White J, Goldstein R (2012). Ferreira, Ivone M, ed. "Nutritional supplementation for stable chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 12: CD000998. doi:10.1002/14651858.CD000998.pub3. PMID 23235577.
  84. ↑ van Dijk WD, van den Bemt L, van Weel C (2013). "Megatrials for bronchodilators in chronic obstructive pulmonary disease (COPD) treatment: time to reflect". J Am Board Fam Med. 26 (2): 221–4. doi:10.3122/jabfm.2013.02.110342. PMID 23471939.
  85. ↑ Liesker JJ, Wijkstra PJ, Ten Hacken NH, Koëter GH, Postma DS, Kerstjens HA (February 2002). "A systematic review of the effects of bronchodilators on exercise capacity in patients with COPD". Chest. 121 (2): 597–608. doi:10.1378/chest.121.2.597. PMID 11834677.
  86. ↑ Chong J, Karner C, Poole P (2012). Chong, Jimmy, ed. "Tiotropium versus long-acting beta-agonists for stable chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 9: CD009157. doi:10.1002/14651858.CD009157.pub2. PMID 22972134.
  87. ↑ Karner C, Cates CJ (2012). Karner, Charlotta, ed. "Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 4: CD008989. doi:10.1002/14651858.CD008989.pub2. PMID 22513969.
  88. 1 2 3 4 5 6 7 8 Vestbo, Jørgen (2013). "Therapeutic Options" (PDF). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease. pp. 19–30.
  89. 1 2 Cave, AC.; Hurst, MM. (May 2011). "The use of long acting β₂-agonists, alone or in combination with inhaled corticosteroids, in chronic obstructive pulmonary disease (COPD): a risk-benefit analysis". Pharmacol Ther. 130 (2): 114–43. doi:10.1016/j.pharmthera.2010.12.008. PMID 21276815.
  90. ↑ Spencer, S; Karner, C; Cates, CJ; Evans, DJ (Dec 7, 2011). Spencer, Sally, ed. "Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease". Cochrane Database Syst Rev (12): CD007033. doi:10.1002/14651858.CD007033.pub3. PMID 22161409.
  91. ↑ Wang, J; Nie, B; Xiong, W; Xu, Y (April 2012). "Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis". Journal of clinical pharmacy and therapeutics. 37 (2): 204–11. doi:10.1111/j.1365-2710.2011.01285.x. PMID 21740451.
  92. ↑ Decramer ML, Hanania NA, Lötvall JO, Yawn BP (2013). "The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease". Int J Chron Obstruct Pulmon Dis. 8: 53–64. doi:10.2147/COPD.S39018. PMC 3558319Freely accessible. PMID 23378756.
  93. ↑ Nannini, LJ; Lasserson, TJ; Poole, P (Sep 12, 2012). Nannini, Luis Javier, ed. "Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 9: CD006829. doi:10.1002/14651858.CD006829.pub2. PMID 22972099.
  94. ↑ Karner C, Chong J, Poole P (2012). Karner, Charlotta, ed. "Tiotropium versus placebo for chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 7: CD009285. doi:10.1002/14651858.CD009285.pub2. PMID 22786525.
  95. ↑ Cheyne L, Irvin-Sellers MJ, White J (Sep 16, 2013). Cheyne, Leanne, ed. "Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 9 (9): CD009552. doi:10.1002/14651858.CD009552.pub2. PMID 24043433.
  96. ↑ Karner, C; Chong, J; Poole, P (Jul 11, 2012). Karner, Charlotta, ed. "Tiotropium versus placebo for chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 7: CD009285. doi:10.1002/14651858.CD009285.pub2. PMID 22786525.
  97. ↑ Singh S, Loke YK, Furberg CD (September 2008). "Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis". JAMA. 300 (12): 1439–50. doi:10.1001/jama.300.12.1439. PMID 18812535.
  98. ↑ Singh S, Loke YK, Enright P, Furberg CD (January 2013). "Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications". Thorax. 68 (1): 114–6. doi:10.1136/thoraxjnl-2011-201275. PMID 22764216.
  99. ↑ Jones, P (Apr 2013). "Aclidinium bromide twice daily for the treatment of chronic obstructive pulmonary disease: a review.". Advances in therapy. 30 (4): 354–68. doi:10.1007/s12325-013-0019-2. PMID 23553509.
  100. ↑ Cazzola, M; Page, CP; Matera, MG (Jun 2013). "Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.". Expert opinion on pharmacotherapy. 14 (9): 1205–14. doi:10.1517/14656566.2013.789021. PMID 23566013.
  101. ↑ Gartlehner G, Hansen RA, Carson SS, Lohr KN (2006). "Efficacy and Safety of Inhaled Corticosteroids in Patients With COPD: A Systematic Review and Meta-Analysis of Health Outcomes". Ann Fam Med. 4 (3): 253–62. doi:10.1370/afm.517. PMC 1479432Freely accessible. PMID 16735528.
  102. ↑ Chinet, T; Dumoulin, J; Honore, I; Braun, JM; Couderc, LJ; Febvre, M; Mangiapan, G; Maurer, C; Serrier, P; Soyez, F; Terrioux, P; Jebrak, G (29 January 2016). "[The place of inhaled corticosteroids in COPD].". Revue des maladies respiratoires. doi:10.1016/j.rmr.2015.11.009. PMID 26831345.
  103. ↑ Dong, YH; Lin, HH; Shau, WY; Wu, YC; Chang, CH; Lai, MS (January 2013). "Comparative safety of inhaled medications in patients with chronic obstructive pulmonary disease: systematic review and mixed treatment comparison meta-analysis of randomised controlled trials.". Thorax. 68 (1): 48–56. doi:10.1136/thoraxjnl-2012-201926. PMID 23042705.
  104. ↑ Nannini, LJ; Poole, P; Milan, SJ; Kesterton, A (30 August 2013). "Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease.". Cochrane Database Syst Rev. 8: CD006826. doi:10.1002/14651858.CD006826.pub2. PMID 23990350.
  105. ↑ Kew, KM; Seniukovich, A (10 March 2014). "Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease.". Cochrane Database Syst Rev. 3: CD010115. doi:10.1002/14651858.CD010115.pub2. PMID 24615270.
  106. ↑ Mammen MJ, Sethi S (2012). "Macrolide therapy for the prevention of acute exacerbations in chronic obstructive pulmonary disease". Pol. Arch. Med. Wewn. 122 (1–2): 54–9. PMID 22353707.
  107. 1 2 Herath, SC; Poole, P (Nov 28, 2013). "Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD).". Cochrane Database Syst Rev. 11: CD009764. doi:10.1002/14651858.CD009764.pub2. PMID 24288145.
  108. ↑ Simoens, S; Laekeman, G; Decramer, M (May 2013). "Preventing COPD exacerbations with macrolides: a review and budget impact analysis". Respiratory medicine. 107 (5): 637–48. doi:10.1016/j.rmed.2012.12.019. PMID 23352223.
  109. ↑ Barr RG, Rowe BH, Camargo CA (2003). Barr, R Graham, ed. "Methylxanthines for exacerbations of chronic obstructive pulmonary disease". Cochrane Database Syst Rev (2): CD002168. doi:10.1002/14651858.CD002168. PMID 12804425.
  110. ↑ Poole, P; Chong, J; Cates, CJ (29 July 2015). "Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease.". Cochrane Database Syst Rev. 7: CD001287. doi:10.1002/14651858.CD001287.pub5. PMID 26222376.
  111. 1 2 COPD Working, Group (2012). "Long-term oxygen therapy for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis". Ontario health technology assessment series. 12 (7): 1–64. PMC 3384376Freely accessible. PMID 23074435.
  112. ↑ Bradley JM, O'Neill B (2005). Bradley, Judy M, ed. "Short-term ambulatory oxygen for chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 4: CD004356. doi:10.1002/14651858.CD004356.pub3. PMID 16235359.
  113. ↑ Uronis H, McCrory DC, Samsa G, Currow D, Abernethy A (2011). Abernethy, Amy, ed. "Symptomatic oxygen for non-hypoxaemic chronic obstructive pulmonary disease". Cochrane Database Syst Rev (6): CD006429. doi:10.1002/14651858.CD006429.pub2. PMID 21678356.
  114. ↑ Chapman, Stephen (2009). Oxford handbook of respiratory medicine (2nd ed.). Oxford University Press. p. 707. ISBN 978-0-19-954516-2.
  115. ↑ Blackler, Laura (2007). Managing chronic obstructive pulmonary disease. Wiley. p. 49. ISBN 978-0-470-51798-7.
  116. ↑ Jindal, Surinder K (2013). Chronic Obstructive Pulmonary Disease. Jaypee Brothers Medical. p. 139. ISBN 978-93-5090-353-7.
  117. 1 2 O'Driscoll, BR; Howard, LS; Davison, AG; British Thoracic, Society (October 2008). "BTS guideline for emergency oxygen use in adult patients". Thorax. 63 (Suppl 6): vi1–68. doi:10.1136/thx.2008.102947. PMID 18838559.
  118. ↑ van Agteren, JE; Carson, KV; Tiong, LU; Smith, BJ (14 October 2016). "Lung volume reduction surgery for diffuse emphysema.". The Cochrane database of systematic reviews. 10: CD001001. PMID 27739074.
  119. ↑ "Bronchodilators delivered by nebuliser versus inhalers for lung attacks of chronic obstructive pulmonary disease". 29 August 2016. doi:10.1002/14651858.cd011826.
  120. ↑ Walters, JA; Tan, DJ; White, CJ; Gibson, PG; Wood-Baker, R; Walters, EH (September 2014). "Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 9: CD001288. doi:10.1002/14651858.CD001288.pub4. PMID 25178099.
  121. ↑ Walters, JA; Tan, DJ; White, CJ; Wood-Baker, R (10 December 2014). "Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease.". Cochrane Database Syst Rev. 12: CD006897. doi:10.1002/14651858.CD006897.pub3. PMID 25491891.
  122. 1 2 Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA (2012). Vollenweider, Daniela J, ed. "Antibiotics for exacerbations of chronic obstructive pulmonary disease". Cochrane Database Syst Rev. 12: CD010257. doi:10.1002/14651858.CD010257. PMID 23235687.
  123. ↑ "Fluoroquinolone Antibacterial Drugs: Drug Safety Communication - FDA Advises Restricting Use for Certain Uncomplicated Infections". FDA. 12 May 2016. Retrieved 16 May 2016.
  124. ↑ "WHO Disease and injury country estimates". World Health Organization. 2009. Retrieved Nov 11, 2009.
  125. 1 2 Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, Ezzati M, Shibuya K, Salomon JA, et al. (December 2012). "Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2197–223. doi:10.1016/S0140-6736(12)61689-4. PMID 23245608.
  126. ↑ Medicine, prepared by the Department of Medicine, Washington University School of (2009). The Washington manual general internal medicine subspecialty consult. (2nd ed.). Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 96. ISBN 978-0-7817-9155-7.
  127. ↑ "Chronic obstructive pulmonary disease (COPD) Fact sheet N°315". WHO. January 2015.
  128. ↑ Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, et al. (December 2012). "Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010". Lancet. 380 (9859): 2095–128. doi:10.1016/S0140-6736(12)61728-0. PMID 23245604.
  129. ↑ "The 10 leading causes of death in the world, 2000 and 2011". World Health Organization. July 2013. Retrieved November 29, 2013.
  130. ↑ Rycroft CE, Heyes A, Lanza L, Becker K (2012). "Epidemiology of chronic obstructive pulmonary disease: a literature review". Int J Chron Obstruct Pulmon Dis. 7: 457–94. doi:10.2147/COPD.S32330. PMC 3422122Freely accessible. PMID 22927753.
  131. ↑ Simpson CR, Hippisley-Cox J, Sheikh A (2010). "Trends in the epidemiology of chronic obstructive pulmonary disease in England: a national study of 51 804 patients". Brit J Gen Pract. 60 (576): 483–8. doi:10.3399/bjgp10X514729. PMC 2894402Freely accessible. PMID 20594429.
  132. ↑ Centers for Disease Control and Prevention (23 November 2012). "Chronic Obstructive Pulmonary Disease Among Adults — United States, 2011". Morbidity and Mortality Weekly Report. 61 (46): 938–43. PMID 23169314.
  133. ↑ "Morbidity & Mortality: 2009 Chart Book on Cardiovascular, Lung, and Blood Diseases" (PDF). National Heart, Lung, and Blood Institute. Archived from the original (PDF) on 2013-10-19.
  134. 1 2 Torio CM, Andrews RM (2006). "National Inpatient Hospital Costs: The Most Expensive Conditions by Payer, 2011: Statistical Brief #160". Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Agency for Health Care Policy and Research. PMID 24199255.
  135. ↑ Hoyert, DL; Xu, J (10 October 2012). "Deaths: preliminary data for 2011.". National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System. 61 (6): 1–51. PMID 24984457.
  136. ↑ "Emphysema". Dictionary.com. Retrieved 21 November 2013.
  137. 1 2 Ziment, Irwin (1991). "History of the Treatment of Chronic Bronchitis". Respiration. 58 (Suppl 1): 37–42. doi:10.1159/000195969. PMID 1925077.
  138. 1 2 3 4 Petty TL (2006). "The history of COPD". Int J Chron Obstruct Pulmon Dis. 1 (1): 3–14. doi:10.2147/copd.2006.1.1.3. PMC 2706597Freely accessible. PMID 18046898.
  139. 1 2 Wright, Joanne L.; Churg, Andrew (2008). "Pathologic Features of Chronic Obstructive Pulmonary Disease: Diagnostic Criteria and Differential Diagnosis" (PDF). In Fishman, Alfred; Elias, Jack; Fishman, Jay; Grippi, Michael; Senior, Robert; Pack, Allan. Fishman's Pulmonary Diseases and Disorders (4th ed.). McGraw-Hill. pp. 693–705. ISBN 978-0-07-164109-8.
  140. ↑ Waldbott, George L. (1965). A struggle with Titans. Carlton Press. p. 6.
  141. ↑ Fishman AP (May 2005). "One hundred years of chronic obstructive pulmonary disease". Am. J. Respir. Crit. Care Med. 171 (9): 941–8. doi:10.1164/rccm.200412-1685OE. PMID 15849329.
  142. ↑ Yuh-Chin, T. Huang (2012). A clinical guide to occupational and environmental lung diseases. Humana Press. p. 266. ISBN 978-1-62703-149-3.
  143. ↑ "Pink Puffer – definition of Pink Puffer in the Medical dictionary – by the Free Online Medical Dictionary, Thesaurus and Encyclopedia". Medical-dictionary.thefreedictionary.com. Retrieved 2013-07-23.
  144. 1 2 3 Weinberger, Steven E. (2013). Principles of pulmonary medicine (6th ed.). Elsevier/Saunders. p. 165. ISBN 978-1-62703-149-3.
  145. ↑ Des Jardins, Terry (2013). Clinical Manifestations & Assessment of Respiratory Disease (6th ed.). Elsevier Health Sciences. p. 176. ISBN 978-0-323-27749-5.
  146. ↑ An outcomes strategy for people with chronic obstructive pulmonary disease (COPD) and asthma in England (PDF). Department of Health. 18 July 2011. p. 5. Retrieved 27 November 2013.
  147. ↑ Bloom, D (2011). The Global Economic Burden of Noncommunicable Diseases (PDF). World Economic Forum. p. 24.
  148. ↑ Nici, Linda (2011). Chronic Obstructive Pulmonary Disease: Co-Morbidities and Systemic Consequences. Springer. p. 78. ISBN 978-1-60761-673-3.
  149. ↑ Inamdar, AC; Inamdar, AA (October 2013). "Mesenchymal stem cell therapy in lung disorders: pathogenesis of lung diseases and mechanism of action of mesenchymal stem cell.". Experimental lung research. 39 (8): 315–27. doi:10.3109/01902148.2013.816803. PMID 23992090.
  150. ↑ Conese, M; Piro, D; Carbone, A; Castellani, S; Di Gioia, S (2014). "Hematopoietic and mesenchymal stem cells for the treatment of chronic respiratory diseases: role of plasticity and heterogeneity.". TheScientificWorldJournal. 2014: 859817. doi:10.1155/2014/859817. PMC 3916026Freely accessible. PMID 24563632.
  151. ↑ McQualter, JL; Anthony, D; Bozinovski, S; Prêle, CM; Laurent, GJ (November 2014). "Harnessing the potential of lung stem cells for regenerative medicine.". The international journal of biochemistry & cell biology. 56: 82–91. doi:10.1016/j.biocel.2014.10.012. PMID 25450456.
  152. ↑ Tzouvelekis, A; Ntolios, P; Bouros, D (2013). "Stem cell treatment for chronic lung diseases.". Respiration; international review of thoracic diseases. 85 (3): 179–92. doi:10.1159/000346525. PMID 23364286.
  153. ↑ Tzouvelekis, A; Laurent, G; Bouros, D (February 2013). "Stem cell therapy in chronic obstructive pulmonary disease. Seeking the Prometheus effect.". Current drug targets. 14 (2): 246–52. doi:10.2174/1389450111314020009. PMID 23256721.
  154. ↑ Gompelmann, D; Eberhardt, R; Herth, FJ (August 2015). "Novel Endoscopic Approaches to Treating Chronic Obstructive Pulmonary Disease and Emphysema.". Seminars in respiratory and critical care medicine. 36 (4): 609–15. doi:10.1055/s-0035-1555614. PMID 26238645.
  155. ↑ Akers, R. Michael; Denbow, D. Michael (2008). Anatomy and Physiology of Domestic Animals. Wiley. p. 852. ISBN 978-1-118-70115-7.
  156. ↑ Wright, JL; Churg, A (December 2002). "Animal models of cigarette smoke-induced COPD". Chest. 122 (6 Suppl): 301S–6S. doi:10.1378/chest.122.6_suppl.301S. PMID 12475805.
  157. ↑ Churg, A; Wright, JL (2007). "Animal models of cigarette smoke-induced chronic obstructive lung disease". Contributions to microbiology. Contributions to Microbiology. 14: 113–25. doi:10.1159/000107058. ISBN 3-8055-8332-X. PMID 17684336.
  158. ↑ Marinkovic D, Aleksic-Kovacevic S, Plamenac P (2007). "Cellular basis of chronic obstructive pulmonary disease in horses". Int. Rev. Cytol. International Review of Cytology. 257: 213–47. doi:10.1016/S0074-7696(07)57006-3. ISBN 978-0-12-373701-4. PMID 17280899.
  159. ↑ Miller MS, Tilley LP, Smith FW (January 1989). "Cardiopulmonary disease in the geriatric dog and cat". Vet. Clin. North Am. Small Anim. Pract. 19 (1): 87–102. PMID 2646821.

Further reading

External links

Wikimedia Commons has media related to Chronic obstructive pulmonary disease.
This article is issued from Wikipedia - version of the 11/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.